Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 4 Recruiting 2 Completed 2 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Hepatocellular 2 Urinary Bladder Neoplasms 1 Neuroendocrine Tumors 1 Differentiated Thyroid Cancer (DTC) 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

lutetium Lu 177 dotatate 4 lanreotide 3 (177)Lu-DOTA-EB-TATE 3 Positron Emission Tomography Computed Tomography 2 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2 Metformin 2 Fluorodeoxyglucose F18 2 Everolimus 2 Capecitabine 2 Biopsy 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 sintilimab 1 recombinant interferon alpha 2b-like protein 1 gallium Ga 68 dotatate 1 copper dotatate CU-64 1 cabozantinib 1 anlotinib 1 amino-acid, glucose, and electrolyte solution 1 Yttrium-90 1 Tomography, Emission-Computed, Single-Photon 1 Temozolomide 1 Surgical Procedures, Operative 1 Somatostatin 1 Plastic Surgery Procedures 1 Phlebotomy 1 Nivolumab 1 Needles 1 Magnetic Resonance Spectroscopy 1 Lysine 1 Lutetium-177 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Neuroendocrine Tumors × cabozantinib × Clear all

NCT04427787 2021-09-05

LOLA

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Unknown

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡